1095 related articles for article (PubMed ID: 21112898)
1. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
[TBL] [Abstract][Full Text] [Related]
2. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
[TBL] [Abstract][Full Text] [Related]
3. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
Linde C; Gold M; Abraham WT; Daubert JC;
Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
[TBL] [Abstract][Full Text] [Related]
6. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
Linde C; Gold MR; Abraham WT; St John Sutton M; Ghio S; Cerkvenik J; Daubert C;
Eur Heart J; 2013 Sep; 34(33):2592-9. PubMed ID: 23641006
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.
Poggio R; Augustovsky F; Caporale J; Irazola V; Miriuka S
Int J Technol Assess Health Care; 2012 Oct; 28(4):429-35. PubMed ID: 23006489
[TBL] [Abstract][Full Text] [Related]
9. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.
Abraham WT; Young JB; León AR; Adler S; Bank AJ; Hall SA; Lieberman R; Liem LB; O'Connell JB; Schroeder JS; Wheelan KR;
Circulation; 2004 Nov; 110(18):2864-8. PubMed ID: 15505095
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain.
Almenar L; Díaz B; Quesada A; Crespo C; Martí B; Mealing S; Linde C; Daubert C
Int J Technol Assess Health Care; 2013 Apr; 29(2):140-6. PubMed ID: 23552131
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
Linde C; Abraham WT; Gold MR; St John Sutton M; Ghio S; Daubert C;
J Am Coll Cardiol; 2008 Dec; 52(23):1834-1843. PubMed ID: 19038680
[TBL] [Abstract][Full Text] [Related]
13. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).
Gold MR; Daubert JC; Abraham WT; Hassager C; Dinerman JL; Hudnall JH; Cerkvenik J; Linde C
Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1163-8. PubMed ID: 24125796
[TBL] [Abstract][Full Text] [Related]
14. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
[TBL] [Abstract][Full Text] [Related]
16. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.
Gold MR; Thébault C; Linde C; Abraham WT; Gerritse B; Ghio S; St John Sutton M; Daubert JC
Circulation; 2012 Aug; 126(7):822-9. PubMed ID: 22781424
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study.
Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
JACC Heart Fail; 2015 Sep; 3(9):691-700. PubMed ID: 26277764
[TBL] [Abstract][Full Text] [Related]
18. Cardiac resynchronization therapy in patients with systolic left ventricular dysfunction and symptoms of mild heart failure secondary to ischemic or nonischemic cardiomyopathy.
Bleeker GB; Schalij MJ; Holman ER; Steendijk P; van der Wall EE; Bax JJ
Am J Cardiol; 2006 Jul; 98(2):230-5. PubMed ID: 16828599
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
